Loading
companiesCompany
Illumina
Illumina is the dominant DNA sequencing platform underneath nearly every genomic test in oncology.
Overview
Illumina, based in San Diego and listed as ILMN, is the dominant DNA sequencing platform underneath nearly every genomic test in oncology. Its NovaSeq X instruments, the TruSight Oncology 500 panel, approved as an in vitro diagnostic in 2024 to 2025 and carried in OnCo as TruSight Oncology Comprehensive, and a constellation of measurable residual disease and spatial products make it the supplier behind many of the diagnostics companies on this site. OnCo links it to comprehensive genomic profiling and whole-genome sequencing, to new short-read sequencing platforms and clinical bioinformatics, to the CRUK Cambridge Institute, to Illumina Ventures and to the bottleneck that inherited risk is mostly unidentified. Whether new short-read competitors erode its position is the open question. TruSight Oncology Comprehensive has its own page.
Headquarters
San Diego, CA, US
Scorecard
All companies#320of 1244 companies, score 12
- approved products +6
- targets +2
- modalities +2
- regions +2
1 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Type
Diagnostics · ILMN
Stage
Public
Website
ApprovedDistributable tissue NGS companion diagnostic test (500+ genes, DNA and RNA)
TruSight Oncology Comprehensive · TSO Comprehensive
A large gene panel hospitals can run themselves, approved by the FDA in 2024 as a companion diagnostic for the tumour-agnostic drug larotrectinib.
Similar pages
- CompanySOPHiA GENETICS
Shares Clinical NGS bioinformatics and variant interpretation, Comprehensive genomic profiling.
- IdeaStore adult-onset cancer gene results from newborn genomes and disclose at 18
Shares Inherited risk is mostly unidentified, Whole-exome & whole-genome sequencing.
- IdeaUniversal tumour and germline sequencing at diagnosis feeding a shared learning system
Shares Inherited risk is mostly unidentified, Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
- PersonNitzan Rosenfeld
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, Whole-exome & whole-genome sequencing.
- PersonCarlos Caldas
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, Whole-exome & whole-genome sequencing.
- PersonSerena Nik-Zainal
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, Whole-exome & whole-genome sequencing.
- IdeaA standard evolvability score for every tumour
Shares Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
- CompanyValius Sciences
Shares Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
fronts
technologies
drugs
ApprovedDistributable tissue NGS companion diagnostic test (500+ genes, DNA and RNA)
TruSight Oncology Comprehensive · TSO Comprehensive
companies
institutions
bottlenecks
Open-source projects
All open source in oncology →Open-source projects that this organisation maintains, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
Illumina's structural variant and indel caller for paired-end sequencing, with a tumour-normal mode for somatic rearrangements.
Illumina's small-variant caller for germline and somatic sequencing; the somatic mode calls tumour-normal pairs quickly and is a common member of ensemble pipelines.
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
Hardware-accelerated secondary analysis: alignment and variant calling on a field-programmable gate array, which is how many clinical laboratories keep up with their sequencers.
IlluminaPaper 2025An interpretation platform that automates the first pass of variant prioritisation and drafts the evidence behind each call.
IlluminaPaper 2019A large sequencing panel sold as a kit with its own analysis software, so a laboratory can run comprehensive profiling itself.
Illuminano source outside the company found